CN103270047A - Oprf/i剂及其在住院患者和其他患者中的用途 - Google Patents

Oprf/i剂及其在住院患者和其他患者中的用途 Download PDF

Info

Publication number
CN103270047A
CN103270047A CN2011800625695A CN201180062569A CN103270047A CN 103270047 A CN103270047 A CN 103270047A CN 2011800625695 A CN2011800625695 A CN 2011800625695A CN 201180062569 A CN201180062569 A CN 201180062569A CN 103270047 A CN103270047 A CN 103270047A
Authority
CN
China
Prior art keywords
oprf
seq
agent
key
fusion rotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800625695A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·克莱德
罗伯特·施勒格尔
克尔斯汀·韦斯特理施尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austria Co Ltd
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of CN103270047A publication Critical patent/CN103270047A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800625695A 2010-12-23 2011-03-18 Oprf/i剂及其在住院患者和其他患者中的用途 Pending CN103270047A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
CN103270047A true CN103270047A (zh) 2013-08-28

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800625695A Pending CN103270047A (zh) 2010-12-23 2011-03-18 Oprf/i剂及其在住院患者和其他患者中的用途

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
CN114651009A (zh) * 2019-07-23 2022-06-21 格勒诺布尔-阿尔卑斯大学 针对铜绿假单胞菌OprF蛋白的抗体、其作为药物的用途和含有该抗体的药物组合物
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2892688A1 (en) 2012-11-30 2014-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
AU2015308625A1 (en) * 2014-08-29 2017-04-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind OprF and Oprl
NZ774893A (en) * 2015-05-01 2024-11-29 Inhibrx Biosciences Inc Type iii secretion system targeting molecules
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
WO2004063217A1 (ja) * 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha 二量体化ペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP1423129A1 (en) * 2001-09-03 2004-06-02 Anbics Patents-Licences AG Therapeutic process for p. aeruginosa infections using macrolide antibiotics
CA2466474C (en) * 2001-11-13 2012-10-09 Shire Biochem Inc. Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
UA91205C2 (ru) * 2004-12-17 2010-07-12 Венус Ремедиз Лимитед Антибиотическая комбинация амикацина и цефепима для создания общего раствора для лечения инфекций
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
CA2892688A1 (en) * 2012-11-30 2014-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
WO2004063217A1 (ja) * 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha 二量体化ペプチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIRK BUMANN ET AL: "Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers", 《VACCINE》 *
KNAPP,B.D. ET AL: "CAA0334", 《GENBANK》 *
U. BAUMANN ET AL: "RECOMBINANT OprF-OprI AS A VACCINE AGAINST PSEUDOMONAS AERUGINOSA INFECTIONS AERUGINOSA INFECTIONS", 《VACCINE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
CN114651009A (zh) * 2019-07-23 2022-06-21 格勒诺布尔-阿尔卑斯大学 针对铜绿假单胞菌OprF蛋白的抗体、其作为药物的用途和含有该抗体的药物组合物
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Also Published As

Publication number Publication date
AU2011348396A2 (en) 2013-07-11
MX2013007146A (es) 2013-11-01
JP2014504297A (ja) 2014-02-20
US20130266575A1 (en) 2013-10-10
BR112013016254A2 (pt) 2017-07-11
EP2655402A1 (en) 2013-10-30
CA2822684A1 (en) 2012-06-28
AU2011348396A1 (en) 2013-07-04
ZA201304235B (en) 2014-09-25
JP5893640B2 (ja) 2016-03-23
JP2016147867A (ja) 2016-08-18
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
JP5893640B2 (ja) Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
AU2021248665A1 (en) Binding proteins useful against ACE2-targeted viruses
CN112521494B (zh) 一种抗SARS-CoV-2的单克隆抗体2B11
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
CN102686611A (zh) 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
CN110732023B (zh) 一种her2抗体药物组合物及其用途
EP2041165A2 (en) Novel applications for staphylococcus aureus sbi protein
TW202102204A (zh) 包含抗ｉｌ－５抗體的醫藥組成物及其用途
AU2023209795A1 (en) Chimeric polypeptides
WO2016073860A1 (en) Binding molecules specific for staphylococcus protein a and uses thereof
US20160362480A1 (en) Novel oprf/i fusion proteins, their preparation and use
HK1188799A (en) Oprf/i agents and their use in hospitalized and other patients
CN105542003B (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
CN117327174A (zh) 抗新型冠状病毒人源化多价结合蛋白及其应用
US20190194300A1 (en) Variant antibodies that bind aip2
CN113817051A (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
TW202100540A (zh) 一種以重組毒素製作抗蛇毒血清方法
CN113817050A (zh) 一种抗SARS-CoV-2的单克隆抗体1H8
WO2023036814A1 (en) Coronavirus fusion protein
WO2011001882A1 (ja) 緑膿菌に対して効果的に感染防御能を誘導するフラジェリン変異体
MXPA00008111A (en) Group b streptococcus antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: VALNEVA AUSTRIA GMBH

Free format text: FORMER OWNER: INTERCELL AG.

Effective date: 20140326

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140326

Address after: Austria Vienna

Applicant after: Austria Co Ltd

Address before: Austria Vienna

Applicant before: Intercell Ag

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188799

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130828

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1188799

Country of ref document: HK